drugset
drugset / Trial / NCT07538570

Evaluation of Pain Treatment After Total Knee Arthroplasty

NCT07538570 ↗

Phase 4 Recruiting 60 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedSequentialQuadruple-blindTreatment

Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Timeline

Start
2026-04-24
Primary completion
2027-01-30
Completion
2027-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.